

# Helen L Ford

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4385947/publications.pdf>

Version: 2024-02-01

16  
papers

203  
citations

1307366

7  
h-index

1125617

13  
g-index

16  
all docs

16  
docs citations

16  
times ranked

234  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. <i>Practical Neurology</i> , 2023, 23, 6-14.	0.5	13
2	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. <i>Journal of the Neurological Sciences</i> , 2022, 436, 120188.	0.3	3
3	Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS). <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103894.	0.9	2
4	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. <i>Journal of the Neurological Sciences</i> , 2021, 426, 117437.	0.3	19
5	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. <i>BMJ Open</i> , 2021, 11, e050176.	0.8	3
6	Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102507.	0.9	7
7	Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102330.	0.9	13
8	The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments. <i>Patient</i> , 2020, 13, 583-597.	1.1	5
9	Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis. <i>Patient Education and Counseling</i> , 2020, 103, 2540-2547.	1.0	8
10	Tortoise or hare? Supporting the chronotope preference of employees with fluctuating chronic illness symptoms. <i>Psychology and Health</i> , 2019, 34, 695-714.	1.2	4
11	Managing the (In)visibility of Chronic Illness at Work: Dialogism, Parody, and Reported Speech. <i>Qualitative Health Research</i> , 2019, 29, 1213-1226.	1.0	3
12	Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 370-377.	0.9	22
13	Psychological determinants of job retention in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 419-426.	1.4	9
14	A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis. <i>Patient</i> , 2018, 11, 391-402.	1.1	32
15	Multiple sclerosis and employment: Associations of psychological factors and work instability. <i>Journal of Rehabilitation Medicine</i> , 2016, 48, 799-805.	0.8	18
16	Screening for the risk of job loss in multiple sclerosis (MS): development of an MS-specific Work Instability Scale (MS-WIS). <i>Multiple Sclerosis Journal</i> , 2012, 18, 862-870.	1.4	42